Company Information & Drug Savings for Actelion Pharmaceuticals US, Inc. Medications
Actelion Pharmaceuticals, now part of Johnson & Johnson’s Janssen Pharmaceutical Companies, specializes in pulmonary arterial hypertension (PAH) treatments. The company pioneered endothelin receptor antagonist therapy with Tracleer (bosentan) and developed Opsumit (macitentan) and Uptravi (selexipag) for PAH. Actelion’s expertise in rare cardiovascular diseases has helped transform treatment outcomes for patients with life-threatening pulmonary hypertension conditions.
How to Contact Actelion Pharmaceuticals US, Inc.
Phone
1-866-228-3546Medical Disclaimer
NowPatient has taken all reasonable steps to ensure that all material is factually accurate, complete, and current. However, the knowledge and experience of a qualified healthcare professional should always be sought after instead of using the information on this page. Before taking any drug, you should always speak to your doctor or another qualified healthcare provider.
The information provided here about medications is subject to change and is not meant to include all uses, precautions, warnings, directions, drug interactions, allergic reactions, or negative effects. The absence of warnings or other information for a particular medication does not imply that the medication or medication combination is appropriate for all patients or for all possible purposes.
Experienced a Side Effect?
Report to Yellow Card (UK) or MedWatch (US)
